Phase 3 Study of Ibrutinib in Combination With Venetoclax in Subjects With Mantle Cell Lymphoma
Latest Information Update: 26 Jul 2024
At a glance
- Drugs Ibrutinib (Primary) ; Venetoclax (Primary)
- Indications Mantle-cell lymphoma
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms SYMPATICO
- Sponsors Pharmacyclics
- 01 Jul 2024 Status changed from active, no longer recruiting to completed.
- 04 Jun 2024 Results reporting efficacy and safety of Ibr+Ven in pts with TP53 mutations across cohorts, presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 12 Dec 2023 Primary endpoint has been met. (progression-free survival (PFS) by investigator (INV) assessment using Lugano criteria), as per Results presented at the 65th American Society of Hematology Annual Meeting and Exposition